Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,657,484

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Tracey Ryniec headshot

Friday's Best Earnings Charts

by Tracey Ryniec

It's not easy to beat the estimate nearly every quarter.

    Zacks Equity Research

    Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

    by Zacks Equity Research

    Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

      Zacks Equity Research

      AbbVie's HCV Regimen Okayed for Accelerated Assessment

      by Zacks Equity Research

      AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).

        Zacks Equity Research

        Sunesis Offers Updates on SNS-062 and Qinprezo Programs

        by Zacks Equity Research

        Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

          Zacks Equity Research

          Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

          by Zacks Equity Research

          AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

            Zacks Equity Research

            Gilead (GILD) HCV Therapy Application Validated in Europe

            by Zacks Equity Research

            Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

              Zacks Equity Research

              What's in Store for Abbott Labs (ABT) This Earnings Season?

              by Zacks Equity Research

              Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

                Zacks Equity Research

                Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

                by Zacks Equity Research

                Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

                  Zacks Equity Research

                  4 Drug Stocks Poised to Surprise this Earnings Season

                  by Zacks Equity Research

                  Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

                    Zacks Equity Research

                    Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

                    by Zacks Equity Research

                    Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

                      Zacks Equity Research

                      Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

                      by Zacks Equity Research

                      AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

                        Zacks Equity Research

                        4 Best Marijuana Stocks to Play the Green Rush

                        by Zacks Equity Research

                        Not only is marijuana one of the fastest growing industries in the U.S., but it also received a major boost after the 2016 election. Find out which stocks you should play the green rush with.

                          Zacks Equity Research

                          McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?

                          by Zacks Equity Research

                          McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.

                            Zacks Equity Research

                            Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                            by Zacks Equity Research

                            Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

                              Zacks Equity Research

                              Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

                              by Zacks Equity Research

                              Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

                                Zacks Equity Research

                                Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

                                by Zacks Equity Research

                                We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

                                  Zacks Equity Research

                                  Allergan's Uterine Fibroids Candidate Positive in Phase III

                                  by Zacks Equity Research

                                  Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

                                    Zacks Equity Research

                                    What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

                                    by Zacks Equity Research

                                    Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

                                      Zacks Equity Research

                                      Coherus Offers Positive Phase III Data on Humira Biosimilar

                                      by Zacks Equity Research

                                      Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.

                                        Zacks Equity Research

                                        AbbVie's HCV Combo Favorable in Japanese Phase III Study

                                        by Zacks Equity Research

                                        AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

                                          Zacks Equity Research

                                          Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                                          by Zacks Equity Research

                                          Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                                            Zacks Equity Research

                                            Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                                            by Zacks Equity Research

                                            Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                                              Zacks Equity Research

                                              AbbVie's Humira and Imbruvica Drive Performance in 2016

                                              by Zacks Equity Research

                                              AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                                                Zacks Equity Research

                                                Roche (RHHBY) Hemophilia A Drug Positive in Phase III

                                                by Zacks Equity Research

                                                Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

                                                  Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines